These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 14506197)

  • 1. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epratuzumab: targeting B-cell malignancies through CD22.
    Coleman M; Goldenberg DM; Siegel AB; Ketas JC; Ashe M; Fiore JM; Leonard JP
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3991S-4S. PubMed ID: 14506198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
    Carnahan J; Stein R; Qu Z; Hess K; Cesano A; Hansen HJ; Goldenberg DM
    Mol Immunol; 2007 Feb; 44(6):1331-41. PubMed ID: 16814387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD22 as a target of passive immunotherapy.
    Cesano A; Gayko U
    Semin Oncol; 2003 Apr; 30(2):253-7. PubMed ID: 12720147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.
    Postema EJ; Raemaekers JM; Oyen WJ; Boerman OC; Mandigers CM; Goldenberg DM; van Dongen GA; Corstens FH
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3995S-4002S. PubMed ID: 14506199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas JC; Chadburn A; Ely S; Furman RR; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Cesano A; Goldenberg DM
    J Clin Oncol; 2003 Aug; 21(16):3051-9. PubMed ID: 12837807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
    Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking.
    Chaouchi N; Vazquez A; Galanaud P; Leprince C
    J Immunol; 1995 Apr; 154(7):3096-104. PubMed ID: 7534787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive endocytosis and degradation of CD22 by human B cells.
    Shan D; Press OW
    J Immunol; 1995 May; 154(9):4466-75. PubMed ID: 7722303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
    Mattes MJ; Sharkey RM; Karacay H; Czuczman MS; Goldenberg DM
    Clin Cancer Res; 2008 Oct; 14(19):6154-60. PubMed ID: 18829494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
    Leonard JP; Goldenberg DM
    Oncogene; 2007 May; 26(25):3704-13. PubMed ID: 17530024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
    Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
    Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
    Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of the B cell-restricted molecule CD22 on neonatal B lymphocytes depending upon antigen stimulation.
    Viemann D; Schlenke P; Hammers HJ; Kirchner H; Kruse A
    Eur J Immunol; 2000 Feb; 30(2):550-9. PubMed ID: 10671211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
    Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
    Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
    Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.